KNOWLEDGE BANK

Interviews

From Listening to Leading: Reimagining HEOR Through the Lens of Patient-Centred Evidence

Co-Founder & Director, MarksMan Healthcare
Dimple Dang CoFounder of MarksMan Healthcare is a strategic growth architect shaping the firms global footprint She forges highimpact collaborations leads business expansion and builds a talent ecosystem aligned with excellence Her leadership elevates credibility strengthens brand equity and positions MarksMan as a trusted strategic partner delivering value across global healthcare markets

Articles

Futuristic Application of Human-On-A-Chip Technology

The drug development process is highly complex timeconsuming costly and labour intensive There are many steps involved in developing the novel therapeutics including target discovery and validation lead compound identification and optimisation preclinical studies clinical trials and finally the FDA review and approval Even after the development and approval of novel

Research Insights

Feasibility of the Inhibitor Development for Cancer: A Systematic Approach for Drug Design

The traditional Chinese medicine TCM bupleurumgingerlicorice formula presents significant anticancer effects but its active ingredients and inhibitory mechanism remain unclear In this work the core effective ingredient quercetin and its signal transducer and activator of transcription

Case Studies

Analytics Stories: A Case Study from Quintiles

As I have shared within other posts within this series businesses are using analytics to improve their internal and external facing business processes and to strengthen their right to win within the markets that they operate For pharmaceutical businesses strengthening the right to win begins and ends with the drug product development lifecycle I remember for example t...

Techno Trends

HUTCHMED Introduces First-of-its-Kind Savolitinib for Gastric Cancer Treatment

HUTCHMED has introduced firstofitskind savolitinib for the treatment of patients with locally advanced or metastatic gastric cancer or gastroesophageal junction GEJ adenocarcinoma patients with mesenchymal epithelial transition factor MET amplification who have failed to responded to at least two standard treatments

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

Meaningful Advances in Virtual Cells

Brita Belli

Brita Belli is an award-winning science and tech writer and Senior Manager of Communications at Recursion, a clinical-stage TechBio company. Her writing has been featured in the New York Times, National Geographic, MSN.com, and Alternet, and she has covered AI drug discovery and other health tech topics for Future Medicine AI, On Drug Delivery, European Biopharmaceutical Review, and OR Manager Magazine. She’s the author of The Autism Puzzle: Connecting the Dots Between Environmental Toxins and Rising Autism Rates (Seven Stories Press).

2

Decoding Antisense Oligonucleotides: Mechanisms, Applications, and Future Directions

Dr. Arun Shastry

Dr. Arun Shastry is a Bengaluru-based scientist with a PhD in Immunogenetics. He is the Co-Founder, Managing Director, and Chief Scientific Officer (CSO) of Hanugen Therapeutics, a pioneering biopharmaceutical company focused on oligonucleotide-based therapies for rare genetic diseases, particularly Duchenne Muscular Dystrophy (DMD). With over two decades in drug discovery for rare disorders, Dr. Shastry drives affordable, accessible treatments through innovative personalized medicine approaches in India.

3

The Role of Genomics in Shaping the Future of Medicine

Smita Agrawal

Smita Agrawal holds a PhD in Chemical Engineering from the University of California, Berkeley. She has over 20 years of research experience in stem cell biology, neuroscience, immunology, genomics, oncology and real-world data. She currently serves as an independent consultant, offering strategic guidance and insights to life sciences companies on genomics, AI, and health care data applications.

4

Nanoemulsion - A Promising Nanocarrier for Dermal Drug Delivery in Psoriasis

Sindhoor S M

Sindhoor S M is currently working as an Assistant Professor in the Department of Pharmaceutics at Sri Adichunchanagiri College of Pharmacy, Mandya, Karnataka. His areas of specialisation include nanotechnology-based drug delivery system, lipid-based formulations, Topical delivery and gastroretentive in situ gel systems. He has published eight papers based on nanotechnology and lipid-based drug delivery system in peer reviewed indexed journals. Presently he is involved in the development of lipid-based delivery systems.

 

Marina Koland

Marina Koland, is Professor and Head of the Department of Pharmaceutics at the NGSM Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangalore. Her area of specialisation in research is mucoadhesive and nanoparticulate drug delivery. She has published 50 research papers in peer reviewed journals, presented papers at 10 National and 3 International Conferences and worked on several Nitte University funded projects. She is currently working on solid lipid nanoparticles and micelles as drug carriers for targeting.

 

5

Tiny Vesicles, Big Impact

Disha Marwaha

Dr. Disha Marwaha received her PhD in biological sciences from CSIR-Central Drug Research Institute (CSIR-CDRI), India in 2024. She is currently an Assistant Professor at the GLA University, Mathura. She has more than 20 publications in international peer-reviewed Journals. She is an expert in formulation and development, nanomedicine and pharmacokinetics focusing on innovative therapeutic and targeted drug delivery systems.

Neha Singh

Dr. Neha Singh received her Ph.D. in Biological Sciences from the CSIR-Central Drug Research Institute (CSIR-CDRI), India, in 2025. She is currently an Assistant Professor at the Lloyd School of Pharmacy, Greater Noida. Dr. Singh has contributed extensively to the field of pharmaceutical sciences, with many publications, patents, and book chapters in internationally recognised peer-reviewed journals. Her primary research interests include formulation development, nanomedicine and pharmacokinetics, with a focus on innovative therapeutic strategies and targeted drug delivery systems. Dr. Singh’s work reflects her commitment to advancing precision medicine and developing next-generation solutions for healthcare.

press releasesRead more...

Oracle Partners with Wipro to Strengthen End-to-End Pharmacovigilance Services

Oracle Life Sciences announced a partnership with Wipro Limited a leading AIpowered technology services and consulting company to strengthen Wipros pharmacovigilance PV service offering using Oracle Life

Grünenthal acquires cancer treatment Stivarga®

Grnenthal a global leader in pain management and research today announced an agreement with Bayer AG to acquire Stivarga an oral treatment for specific advanced cancers for up to million

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Kazia Therapeutics Limited NASDAQ KZIA an oncologyfocused biotechnology company developing therapies that selectively reprogram cancer biology restore antitumor immunity and overcome treatment resistance

Merck Introduces ‘Science Behind Water’ Campaign to Promote Safe Water Practices

Merck a leading science and technology company launched the Science Behind Water campaign an initiative designed to build awareness around the importance of water quality safety hygiene

AISB Network Launches AISB Bind to Improve Prediction of How Molecules Bind for Virtual Screening and Lead Optimization

The AI Structural Biology AISB Network powered by Apheris today launched AISB Bind a new federated initiative through which AbbVie AstraZeneca Bristol Myers Squibb and Johnson Johnson

Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse

Telix Pharmaceuticals Limited ASX TLX NASDAQ TLX Telix today announces it has signed a strategic agreement to lead a merger with ITM Isotope Technologies Munich SE ITM a global leader

EventsRead more...

21 - 23

Sep 2026

21 - 23

Sep 2026

Cancer R&D World Conference

Hilton Garden Inn Miami Dolphi...

22 - 23

Sep 2026

22 - 24

Sep 2026

28 - 01

Sep 2026

29 - 01

Sep 2026

10th IPF Summit 2026

Boston, MA, USA

29 - 01

Sep 2026

Powtech Technopharm 2026

Nuremberg, Germany

30 - 01

Sep 2026

Pharma Launch Excellence Summit

Hyatt Regency Boston Harbor, B...

LATEST NEWSRead more...

TriSalus Receives FDA Clearance for TriNav Advance for Liver Embolisation

TriSalus Life Sciences has received k clearance from the US Food and Drug Administration FDA for TriNav Advance a new device within its PressureEnabled Drug Delivery PEDD portfolio for liverdirected embolisation procedures

SK pharmteco and GEMMABio Expand Manufacturing Collaboration for SMA Gene Therapy

SK pharmteco and Gemma Biotherapeutics GEMMABio have expanded their manufacturing collaboration to support the clinical development of GB an investigational gene therapy for spinal muscular atrophy type SMA

Merck’s KEYTRUDA QLEX Approved for Subcutaneous Administration

Merck has announced that Japans Ministry of Health Labour and Welfare MHLW has approved KEYTRUDA QLEX pembrolizumab and berahyaluronidase alfapmph for subcutaneous administration

Dualitas Therapeutics and Roche Partner to Discover Bispecific Antibodies for I&I Diseases

Dualitas Therapeutics has announced a research collaboration and licence agreement with Roche to discover and develop novel bispecific antibody BsAb therapies for immunology and inflammation II diseases

Eisai and Biogen Receive Approval for LEQEMBI Pen for Early Alzheimer’s Disease

Eisai and Biogen have received approval in Japan for LEQEMBI Pen a subcutaneous SC formulation of lecanemab for the treatment of early Alzheimers disease AD

QurCan Therapeutics Enters into Collaboration with Lilly Advance Nucleic Acid Therapies for Nervous System Diseases

QurCan Therapeutics has entered into an exclusive research and collaboration agreement with Eli Lilly and Company to develop nucleic acid therapies for diseases affecting the central nervous system CNS and peripheral nervous system PNS